EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer ; volume:21 ; number:1 ; day:11 ; month:1 ; year:2021 ; pages:1-13 ; date:12.2021
BMC cancer ; 21, Heft 1 (11.1.2021), 1-13, 12.2021
- Urheber
-
Okamura, Shunsuke
Yoshino, Hirofumi
Kuroshima, Kazuki
Tsuruda, Masafumi
Osako, Yoichi
Sakaguchi, Takashi
Yonemori, Masaya
Yamada, Yasutoshi
Tatarano, Shuichi
Nakagawa, Masayuki
Enokida, Hideki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-07717-0
- URN
-
urn:nbn:de:101:1-2021030220215701224722
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Okamura, Shunsuke
- Yoshino, Hirofumi
- Kuroshima, Kazuki
- Tsuruda, Masafumi
- Osako, Yoichi
- Sakaguchi, Takashi
- Yonemori, Masaya
- Yamada, Yasutoshi
- Tatarano, Shuichi
- Nakagawa, Masayuki
- Enokida, Hideki
- SpringerLink (Online service)
Ähnliche Objekte (12)
New approaches for cisplatin-resistant bladder cancer
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p
A ‘golden’ alternative for prevention of cisplatin nephrotoxicity in bladder cancer
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer
CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity
Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape
Core promoter mutation contributes to abnormal gene expression in bladder cancer
MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
New approaches for cisplatin-resistant bladder cancer
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p
A ‘golden’ alternative for prevention of cisplatin nephrotoxicity in bladder cancer
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer
CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity
Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape
Core promoter mutation contributes to abnormal gene expression in bladder cancer
MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
New approaches for cisplatin-resistant bladder cancer
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p
A ‘golden’ alternative for prevention of cisplatin nephrotoxicity in bladder cancer
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer
CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity
Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape
Core promoter mutation contributes to abnormal gene expression in bladder cancer